Cantor Fitzgerald Reaffirms “Overweight” Rating for MiMedx Group (NASDAQ:MDXG)

Cantor Fitzgerald reaffirmed their overweight rating on shares of MiMedx Group (NASDAQ:MDXG) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $13.00 price target on the stock.

Separately, StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, MiMedx Group currently has an average rating of “Buy” and a consensus price target of $12.40.

MiMedx Group Stock Up 1.6 %

Shares of MiMedx Group stock opened at $8.14 on Thursday. The company has a fifty day moving average price of $8.74 and a 200 day moving average price of $7.68. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group has a twelve month low of $5.47 and a twelve month high of $10.14. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of 14.80 and a beta of 1.94.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. Equities research analysts forecast that MiMedx Group will post 0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

Several institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC raised its holdings in MiMedx Group by 133.6% in the third quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock valued at $1,806,000 after acquiring an additional 174,797 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock valued at $1,757,000 after purchasing an additional 215,995 shares in the last quarter. Barclays PLC lifted its position in shares of MiMedx Group by 163.9% during the third quarter. Barclays PLC now owns 262,449 shares of the company’s stock worth $1,550,000 after purchasing an additional 163,005 shares during the last quarter. Farther Finance Advisors LLC grew its stake in MiMedx Group by 88.6% in the third quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company’s stock worth $145,000 after purchasing an additional 11,557 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its holdings in MiMedx Group by 299.9% in the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after buying an additional 770,744 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.